| 1 |
Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe |
|
|
| Maria Elisa Mancuso, Giancarlo Castaman, Michal Pochopien, Samuel Aballéa, Aleksandra Drzewiecka, Zalmai Hakimi, Jameel Nazir, Francis Fatoye |
|
| Journal of Medical Economics. 2022; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Effectiveness of Prophylactic Coagulation Factor Replacement Therapy in Patients with Severe Hemophilia A in Taiwan – A Population-Based Study |
|
|
| Miyuki Hsing-Chun Hsieh, Shyh-Shin Chiou, Tzu-Chi Liao, Shi-Jie Lai, Edward Chia-Cheng Lai |
|
| Clinical Epidemiology. 2022; Volume 14: 1501 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Determination of reference intervals from a laboratory database of an academic clinical research unit in a tertiary care teaching hospital and an audit of out of range values |
|
|
| BrinalH Figer, JeffreyPradeep Raj, SaketJ Thaker, NithyaJaideep Gogtay, UrmilaMukund Thatte |
|
| Perspectives in Clinical Research. 2021; 12(4): 193 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Trends in coagulation factor replacement therapy and medical costs in patients with haemophilia in Taiwan: A population-based, 15-year analysis |
|
|
| Miyuki Hsing-Chun Hsieh, Shyh-Shin Chiou, Tzu-Chi Liao, Yea-Huei Kao Yang, Edward Chia-Cheng Lai |
|
| Haemophilia. 2021; 27(2) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Cost-of-illness studies in rare diseases: a scoping review |
|
|
| Lidia García-Pérez, Renata Linertová, Cristina Valcárcel-Nazco, Manuel Posada, Inigo Gorostiza, Pedro Serrano-Aguilar |
|
| Orphanet Journal of Rare Diseases. 2021; 16(1) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Economic burden of hemophilia A and B: a case in Iran |
|
|
| Khosro Keshavarz, Mohammadreza Bordbar, Zeinab Hashemipoor, Farideh Sadat Jalali, Ramin Ravangard |
|
| Hematology. 2020; 25(1): 149 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
